About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Pennsylvania | 9,383 Studies Near You | Clareo Health

Clinical Trials LocationsPennsylvania

Clinical Trials in Pennsylvania

Discover 9,383 clinical trials near Pennsylvania. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1701-1720 of 9,383 trials

COMPLETEDPhase 229 miles

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Plaque Psoriasis

Eli Lilly and Company33 participantsStarted Dec 2023

Los Angeles, California, United States • Santa Monica, California, United States • Coral Gables, Florida, United States +9 more locations

COMPLETEDPhase 265 miles

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Arthritis, Rheumatoid

Janssen Research & Development, LLC103 participantsStarted Aug 2023

Phoenix, Arizona, United States • Huntington Beach, California, United States • Upland, California, United States +29 more locations

Find Trials by Condition in Pennsylvania

Breast Cancerin Pennsylvania Lung Cancerin Pennsylvania Prostate Cancerin Pennsylvania Colorectal Cancerin Pennsylvania Melanomain Pennsylvania Leukemiain Pennsylvania Lymphomain Pennsylvania Pancreatic Cancerin Pennsylvania Ovarian Cancerin Pennsylvania Brain Cancerin Pennsylvania

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 295 miles

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741

The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)

DENV-3 Controlled Human Infection Model

AbViro LLC85 participantsStarted Jan 2025

Baltimore, Maryland, United States • Baltimore, Maryland, United States • Burlington, Vermont, United States

Active Not RecruitingNA95 miles

PERIGON Pivotal Trial

NCT02088554

To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.

Aortic Stenosis

Medtronic Cardiac Surgery1,312 participantsStarted May 2014

Los Angeles, California, United States • Aurora, Colorado, United States • Hartford, Connecticut, United States +35 more locations

Active Not RecruitingPhase 295 miles

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Invasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7+1 more

National Cancer Institute (NCI)67 participantsStarted Aug 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +11 more locations

COMPLETEDPhase 195 miles

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936

This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).

Acute Myelogenous Leukemia

Therapeutic Advances in Childhood Leukemia Consortium37 participantsStarted Jul 2017

Los Angeles, California, United States • Orange, California, United States • San Francisco, California, United States +30 more locations

COMPLETED95 miles

SUBLOCADE Long-term Outcomes

NCT05860959

This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.

Opioid Use Disorder

Indivior Inc.480 participantsStarted Aug 2023

Costa Mesa, California, United States • Escondido, California, United States • Westport, Connecticut, United States +46 more locations

RECRUITING95 miles

Biliary Atresia Study in Infants and Children

NCT00345553

Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To characterize the natural history of the older, non-transplanted child with BA.

Biliary Atresia

Arbor Research Collaborative for Health1,265 participantsStarted May 2006

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +13 more locations

RECRUITING99 miles

A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data

NCT06877884

This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

N-Power Medicine20,000 participantsStarted Aug 2022

Monterey, California, United States • Dover, Delaware, United States • Milford, Delaware, United States +4 more locations

Active Not RecruitingPhase 2/3117 miles

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

NCT03022825

This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus N-803 or N-803 only weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36. The study duration is 60 months.

ImmunityBio, Inc.190 participantsStarted Jun 2017

Anchorage, Alaska, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +25 more locations

Active Not RecruitingPhase 1/2117 miles

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986

The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.

Breast CancerDCISInvasive Duct Carcinoma of Breast

Integro Theranostics100 participantsStarted Jul 2023

Scottsdale, Arizona, United States • Washington D.C., District of Columbia, United States • Weston, Florida, United States +6 more locations

RECRUITINGPhase 1118 miles

Gilteritinib for the Treatment of ALK NSCLC

NCT06225427

This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilteritinib against these resistant cells. Therefore, in this clinical trial, the investigators plan to study the effect of giltertinib in patients with ALK NSCLC.

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

University of Michigan Rogel Cancer Center30 participantsStarted Jul 2024

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Ann Arbor, Michigan, United States

Active Not RecruitingPhase 2118 miles

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066

Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Merck Sharp & Dohme LLC150 participantsStarted Apr 2025

San Francisco, California, United States • West Hollywood, California, United States • Washington D.C., District of Columbia, United States +20 more locations

Active Not RecruitingPhase 1121 miles

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

NCT06188208

A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

Advanced Solid TumorsAdvanced Hematologic Tumors

Vividion Therapeutics, Inc.125 participantsStarted Jan 2024

Los Angeles, California, United States • Sarasota, Florida, United States • Nashville, Tennessee, United States +17 more locations

TERMINATEDPhase 1/2140 miles

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

NCT04541017

This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types of T-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Magrolimab and mogamulizumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Treatment with magrolimab in combination with mogamulizumab may stabilize cancer for longer period than the usual treatment in patients with relapsed/refractory T-cell lymphoma who have been previously treated.

Mycosis FungoidesRecurrent Mycosis FungoidesRecurrent Mycosis Fungoides and Sezary Syndrome+9 more

National Cancer Institute (NCI)8 participantsStarted Apr 2021

Duarte, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +15 more locations

RECRUITINGPhase 2147 miles

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

NCT07041281

The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.

PreeclampsiaGestational Hypertension

Massachusetts General Hospital204 participantsStarted Oct 2025

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Pittsburgh, Pennsylvania, United States

TERMINATEDPhase 1167 miles

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

Advanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell Carcinoma+15 more

Incyte Corporation105 participantsStarted Mar 2021

Hackensack, New Jersey, United States • Greenville, South Carolina, United States • Nashville, Tennessee, United States +21 more locations

COMPLETEDPhase 2168 miles

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

NCT03782792

To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

Generalized Pustular Psoriasis

Boehringer Ingelheim53 participantsStarted Jan 2019

Birmingham, Alabama, United States • Miami, Florida, United States • Tampa, Florida, United States +34 more locations

TERMINATEDPhase 1168 miles

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Metastatic Castration-resistant Prostate CancerProstate Cancer

Amgen212 participantsStarted Feb 2019

Campbell, California, United States • Duarte, California, United States • Long Beach, California, United States +27 more locations

TERMINATEDPhase 2168 miles

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

NCT04878432

The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).

Myelodysplastic Syndrome (MDS)

Novartis Pharmaceuticals39 participantsStarted Mar 2022

Phoenix, Arizona, United States • Tucson, Arizona, United States • Denver, Colorado, United States +12 more locations

PreviousPage 86 of 470Next

Diabetes

in Pennsylvania

Heart Diseasein Pennsylvania